Fluticasone Propionate And Salmeterol Powder, Metered
Product Images NDC 63629-8810

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 63629-8810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fp Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 1)

Fp Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 1)
FDA Label Image

Figure 8 (Fluticasone Propionate Salmeterol Inhalation Powde 10)

Figure 8 (Fluticasone Propionate Salmeterol Inhalation Powde 10)
FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 11)

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 11)
FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 12)

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 12)
FDA Label Image

Figurr A (Fluticasone Propionate Salmeterol Inhalation Powde 13)

Figurr A (Fluticasone Propionate Salmeterol Inhalation Powde 13)
This appears to be a description of a medical device. The device includes a dose counter, a mouthpiece, and a yellow cap. The name "Vent" is also mentioned, which may be the brand name of the device. However, without further context, it is impossible to know what the device is used for or how it operates.*
FDA Label Image

Figure B (Fluticasone Propionate Salmeterol Inhalation Powde 14)

Figure B (Fluticasone Propionate Salmeterol Inhalation Powde 14)
This text describes the available doses, both full and empty, for an inhaler. The inhaler contains 60 doses when full and has 0 doses when empty.*
FDA Label Image

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 15)

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 15)
FDA Label Image

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 16)

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 16)
FDA Label Image

Breathe Out Image (Fluticasone Propionate Salmeterol Inhalation Powde 17)

Breathe Out Image (Fluticasone Propionate Salmeterol Inhalation Powde 17)
FDA Label Image

Figure F (Fluticasone Propionate Salmeterol Inhalation Powde 18)

Figure F (Fluticasone Propionate Salmeterol Inhalation Powde 18)
FDA Label Image

Figure G (Fluticasone Propionate Salmeterol Inhalation Powde 19)

Figure G (Fluticasone Propionate Salmeterol Inhalation Powde 19)
FDA Label Image

Salmeterol Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 2)

Salmeterol Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 2)
FDA Label Image

Figure H (Fluticasone Propionate Salmeterol Inhalation Powde 20)

Figure H (Fluticasone Propionate Salmeterol Inhalation Powde 20)
FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 21)

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 21)
FDA Label Image

Figure 1 (Fluticasone Propionate Salmeterol Inhalation Powde 3)

Figure 1 (Fluticasone Propionate Salmeterol Inhalation Powde 3)
FDA Label Image

Figure 2 (Fluticasone Propionate Salmeterol Inhalation Powde 4)

Figure 2 (Fluticasone Propionate Salmeterol Inhalation Powde 4)
FDA Label Image

Figure 3 (Fluticasone Propionate Salmeterol Inhalation Powde 5)

Figure 3 (Fluticasone Propionate Salmeterol Inhalation Powde 5)
FDA Label Image

Figure 4 (Fluticasone Propionate Salmeterol Inhalation Powde 6)

Figure 4 (Fluticasone Propionate Salmeterol Inhalation Powde 6)
This appears to be a table showing data related to inhalers for respiratory treatment, with different dosages and a placebo group. The table includes information about the number of participants tested (N), and the mean change in Forced Expiratory Volume (FEV) over time in liters, with baseline data recorded on Day 1.*
FDA Label Image

Figure 5 (Fluticasone Propionate Salmeterol Inhalation Powde 7)

Figure 5 (Fluticasone Propionate Salmeterol Inhalation Powde 7)
FDA Label Image

Figure 6 (Fluticasone Propionate Salmeterol Inhalation Powde 8)

Figure 6 (Fluticasone Propionate Salmeterol Inhalation Powde 8)
FDA Label Image

Figure 7 (Fluticasone Propionate Salmeterol Inhalation Powde 9)

Figure 7 (Fluticasone Propionate Salmeterol Inhalation Powde 9)
This is a description of a study evaluating the mean change in FEV, or forced expiratory volume, in individuals. The study involved administering doses of FSMDPI at 232 meg/14 mcg and 113 mcg/14 meg, as well as £P MDPI at 232 meg and 113 meg, and a placebo. The number of participants ranged from 58 to 68 per dose. The chart shows the mean change in FEV over the course of 12 hours, with the baseline reading at Day 1 Hour 0.*
FDA Label Image

Label (Lbl636298810)

Label (Lbl636298810)
This is a description of Fluticasone Propionate and Salmeterol Inhalation Powder, which is an oral inhaler medication used to treat asthma and COPD. Each inhalation contains 232 mcg of fluticasone proprionate and 14 mcg of salmeterol base. The medication is packaged with 60 metered inhalations and should be stored at room temperature, away from extreme heat, cold or humidity, and should never be put in water. The product is available by prescription only.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.